AU2016264321B2 - Methods for diagnosing and assessing treatment for Cushing's syndrome - Google Patents

Methods for diagnosing and assessing treatment for Cushing's syndrome Download PDF

Info

Publication number
AU2016264321B2
AU2016264321B2 AU2016264321A AU2016264321A AU2016264321B2 AU 2016264321 B2 AU2016264321 B2 AU 2016264321B2 AU 2016264321 A AU2016264321 A AU 2016264321A AU 2016264321 A AU2016264321 A AU 2016264321A AU 2016264321 B2 AU2016264321 B2 AU 2016264321B2
Authority
AU
Australia
Prior art keywords
sample
gra
subject
activity
fkbp5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016264321A
Other languages
English (en)
Other versions
AU2016264321A1 (en
Inventor
Joseph K. Belanoff
Hazel Hunt
Andreas G. MORAITIS
John Francis UNITT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of AU2016264321A1 publication Critical patent/AU2016264321A1/en
Application granted granted Critical
Publication of AU2016264321B2 publication Critical patent/AU2016264321B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016264321A 2015-05-18 2016-05-18 Methods for diagnosing and assessing treatment for Cushing's syndrome Active AU2016264321B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163130P 2015-05-18 2015-05-18
US62/163,130 2015-05-18
PCT/US2016/033143 WO2016187347A1 (en) 2015-05-18 2016-05-18 Methods for diagnosing and assessing treatment for cushing's syndrome

Publications (2)

Publication Number Publication Date
AU2016264321A1 AU2016264321A1 (en) 2017-11-30
AU2016264321B2 true AU2016264321B2 (en) 2021-02-18

Family

ID=57320595

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016264321A Active AU2016264321B2 (en) 2015-05-18 2016-05-18 Methods for diagnosing and assessing treatment for Cushing's syndrome

Country Status (10)

Country Link
US (3) US10604807B2 (enExample)
EP (1) EP3297728A4 (enExample)
JP (3) JP6755264B2 (enExample)
KR (2) KR20180008627A (enExample)
AU (1) AU2016264321B2 (enExample)
CA (1) CA2984623C (enExample)
IL (2) IL309712A (enExample)
MX (1) MX2017014857A (enExample)
PH (1) PH12017502099B1 (enExample)
WO (1) WO2016187347A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195214B2 (en) 2017-03-01 2019-02-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
CN108389135A (zh) * 2018-03-21 2018-08-10 安徽理工大学 一种基于灰色关联模型的突水水源判别方法
CN113194957A (zh) * 2018-12-21 2021-07-30 科塞普特治疗公司 通过施用糖皮质激素受体调节剂治疗库欣综合征中的高凝血病
EP4157276A4 (en) 2020-05-27 2024-06-12 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4
EP4157275A4 (en) * 2020-05-27 2024-06-05 Corcept Therapeutics Incorporated CONCURRENT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACTORILANTS AND CYP2C8 SUBSTRATES
MX2022014923A (es) * 2020-05-27 2023-01-04 Corcept Therapeutics Inc Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos cyp2c9.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120094945A1 (en) * 2009-01-09 2012-04-19 The Regents Of The University Of California Discovery of Selective Glucocorticoid Receptor Modulators by Multiplexed Reporter Screening

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
JP2004526425A (ja) * 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
EP1616026A1 (en) * 2003-04-14 2006-01-18 Novartis AG Gene expression associated with osteoblast differentiation
CA2736626C (en) * 2008-09-12 2022-12-06 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Genes associated with posttraumatic-stress disorder (ptsd)
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
JP2013090761A (ja) 2011-10-25 2013-05-16 Osaka City Univ 立体視内視鏡装置
NZ701469A (en) 2012-05-25 2017-06-30 Corcept Therapeutics Inc Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US20140170768A1 (en) 2012-12-14 2014-06-19 Joel R. L. Ehrenkranz Method for monitoring and assessing pituitary function

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120094945A1 (en) * 2009-01-09 2012-04-19 The Regents Of The University Of California Discovery of Selective Glucocorticoid Receptor Modulators by Multiplexed Reporter Screening

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE et al., "A measure of glucocorticoid load provided by DNA methylation of Fkbp5 in mice.", Psychopharmacology, (2011), vol. 218, no. 1, pages 303 - 312 *

Also Published As

Publication number Publication date
KR20180008627A (ko) 2018-01-24
EP3297728A4 (en) 2019-07-03
JP2020195401A (ja) 2020-12-10
KR102876869B1 (ko) 2025-10-27
JP6755264B2 (ja) 2020-09-16
US11268145B2 (en) 2022-03-08
US20180100179A1 (en) 2018-04-12
PH12017502099A1 (en) 2018-05-07
CA2984623A1 (en) 2016-11-24
US10604807B2 (en) 2020-03-31
AU2016264321A1 (en) 2017-11-30
KR20240014584A (ko) 2024-02-01
WO2016187347A1 (en) 2016-11-24
PH12017502099B1 (en) 2023-08-30
EP3297728A1 (en) 2018-03-28
JP2020079799A (ja) 2020-05-28
JP2018524562A (ja) 2018-08-30
US20200216905A1 (en) 2020-07-09
IL309712A (en) 2024-02-01
IL255612A (en) 2018-01-31
US20180291451A1 (en) 2018-10-11
MX2017014857A (es) 2018-08-15
CA2984623C (en) 2023-05-02
JP6893264B2 (ja) 2021-06-23

Similar Documents

Publication Publication Date Title
US11268145B2 (en) Methods for treating Cushing's syndrome
Sbiera et al. Driver mutations in USP8 wild-type Cushing’s disease
Tanaka et al. hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes
Gubelmann et al. Identification of the transcription factor ZEB1 as a central component of the adipogenic gene regulatory network
EP2877599B1 (en) Methods and compositions for determining resistance to androgen receptor therapy
Burns et al. Rai1 haploinsufficiency causes reduced Bdnf expression resulting in hyperphagia, obesity and altered fat distribution in mice and humans with no evidence of metabolic syndrome
Ohtsuki et al. A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia
Lee et al. Androgen receptor transcriptionally regulates μ-opioid receptor expression in rat trigeminal ganglia
Padgett et al. Deoxyhypusine synthase, an essential enzyme for hypusine biosynthesis, is required for proper exocrine pancreas development
WO2018223867A1 (zh) 一种前列腺癌的标志物spop及其在指导肿瘤治疗中的应用
Chen et al. Transcription factor E2F-associated phosphoprotein (EAPP), RAM2/CDCA7L/JPO2 (R1), and simian virus 40 promoter factor 1 (Sp1) cooperatively regulate glucocorticoid activation of monoamine oxidase B
Xu et al. NEDD4 protects vascular endothelial cells against Angiotensin II-induced cell death via enhancement of XPO1-mediated nuclear export
Cheng et al. Decreased A20 mRNA and protein expression in peripheral blood mononuclear cells in patients with type 2 diabetes and latent autoimmune diabetes in adults
Gilad et al. Steroid receptor coactivators: from basic research to translational opportunities
JP2015159766A (ja) クッシング症候群の検査方法、検査用バイオマーカー及び治療剤
WO2009045403A2 (en) MENIN REGULATION OF β-ISLET CELL PROLIFERATION
Knotts et al. Molecular characterization of the tumor suppressor candidate 5 gene: Regulation by PPARγ and identification of TUSC5 coding variants in lean and obese humans
WO2025255493A2 (en) Methods for the diagnosis and treatment of alzheimer's disease and chronic hydrocephalus
Sánchez Pascua Carboxylesterase 1 genetic variability, expression and potential for drug-drug interations
WO2017023649A1 (en) Detection of elevated levels of phosphorylated mcm and method of increasing mcm phosphorylation capacity
Karakuz et al. EXPERIMENTAL BIOMEDICAL RESEARCH
Karakuz et al. Is there a relationship between polycystic ovary syndrome and the FABP1 gene rs2197076 single nucleotide polymorphism?
KR20090034932A (ko) 파킨슨씨 질환 치료 및 진단을 위한 ｇｐｒｃ 변형체의 동정 및 용도
WO2009019208A1 (en) Method for identifying compounds modulating adiponectin gene expression
Hynne Glucocorticoid pharmacogenetics in Addison’s disease–The role of the immunophilin FK506-binding protein (FKBP51) for glucocorticoid sensitivity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)